Keyphrases
Non-small Cell Lung Cancer (NSCLC)
69%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
54%
Immune Checkpoint Inhibitors
46%
Overall Survival
24%
Lung Cancer
22%
Nivolumab
18%
Confidence Interval
18%
Progression-free Survival
18%
Non-small Cell Lung Cancer Patients
16%
Chemotherapy
16%
Osimertinib
13%
Hazard Ratio
13%
Median Overall Survival
12%
Cancer Center
12%
ALK-positive Lung Cancer
12%
CNS Metastases
12%
Real-life Cohort
11%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
11%
Venous Thromboembolism
11%
Next-generation Sequencing
10%
Brain Metastases
10%
Partial Response
9%
NSCLC Patients
9%
Objective Response Rate
9%
Adverse Events
9%
Platinum-based Chemotherapy
9%
ROS1
8%
ALK Inhibitor
8%
Consecutive Patients
8%
Circulating Tumor DNA (ctDNA)
8%
Lung
8%
Crizotinib
8%
EGFR mutation
7%
Pembrolizumab
7%
Median Progression-free Survival
7%
Large Cell Neuroendocrine Tumor
7%
PD-L1 Tumor Proportion Score
7%
Response to Therapy
7%
Stereotactic Radiosurgery
7%
High-dose Radiotherapy
7%
Clinical Impact
7%
BRAF mutant
7%
Epidermal Growth Factor Receptor
7%
Mobocertinib
7%
EGFR Exon 20 Insertion
7%
Stage IV Non-small Cell Lung Cancer
7%
Overall Response Rate
7%
Anaplastic Lymphoma Kinase
7%
Systemic Treatment
7%
Israel
7%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Immune Checkpoint Inhibitor
40%
Lung Cancer
34%
Overall Survival
30%
Neoplasm
27%
Progression Free Survival
22%
Epidermal Growth Factor Receptor
22%
Nivolumab
18%
Diseases
17%
Non-Small Cell Lung Cancer
17%
Radiation Therapy
16%
Malignant Neoplasm
14%
Lung
13%
Retrospective Study
12%
Osimertinib
12%
Brain Metastasis
12%
Tyrosine-Kinase Inhibitor
11%
Venous Thromboembolism
11%
Hazard Ratio
10%
Central Nervous System Metastasis
10%
Anaplastic Lymphoma Kinase
10%
Adverse Event
9%
Programmed Death-Ligand 1
9%
Lung Adenocarcinoma
8%
Large Cell
8%
Electrocorticography
8%
Biological Marker
8%
Arm
7%
Neuroendocrine Tumor
7%
Pleura Mesothelioma
7%
Circulating Tumor DNA
7%
Drug Megadose
7%
Crizotinib
7%
Programmed Death 1 Ligand 1
7%
Small Cell Lung Cancer
6%
Next Generation Sequencing
6%
Central Nervous System
6%
Immunotherapy
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Pembrolizumab
5%
Adenocarcinoma
5%
Systemic Therapy
5%
Chemoradiotherapy
5%
Exon
5%
Lung Carcinoma
5%
Magnetic Resonance Imaging
5%
Targeted Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
94%
Chemotherapy
37%
Immune Checkpoint Inhibitor
36%
Lung Cancer
34%
Overall Survival
32%
Epidermal Growth Factor Receptor
28%
Neoplasm
25%
Progression Free Survival
20%
Diseases
19%
Protein Tyrosine Kinase Inhibitor
14%
Adverse Event
13%
Anaplastic Lymphoma Kinase
13%
Retrospective Study
12%
Osimertinib
12%
Nivolumab
11%
Venous Thromboembolism
11%
Crizotinib
10%
Malignant Neoplasm
9%
Brain Metastasis
9%
Pembrolizumab
8%
Systemic Treatment
8%
Pleura Mesothelioma
7%
Circulating Tumor DNA
7%
Programmed Death 1 Ligand 1
7%
Ceritinib
6%
Lung Adenocarcinoma
6%
Immunotherapy
6%
Chemoradiation Therapy
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Adenocarcinoma
5%
Biological Marker
5%
Monotherapy
5%